Meta-analyses indicate that FGFR2 gene amplification occurs in roughly 3–10% of gastric cancers, whereas immunohistochemical assessment demonstrates FGFR2 protein overexpression in a broader subset (~30–40%), implying that protein-level evaluation may identify therapeutically targetable tumors even in the absence of genomic amplification [13]. This evidence concerns the gene FGFR2 and gastric cancer.